{"slug":"pt-141-glp1-gut","verification":{"valid":true,"entries":2,"head":"c613e26a32fd644a3cc2966e3fbe90fa778b6f26165d7906e7c44a73c63ca574"},"count":2,"sources":[{"id":"s0","type":"news","url":"https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/","title":"Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study","quote":"The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1 /GIP tirzepatide treatment.","summary":"Phase 2 results on bremelanotide + tirzepatide for obesity.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:02.106Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"41c499b11caea3327df1edf2d15459d533486ebe7e7a82d387322ca215cd8427"},{"id":"s14","type":"medical","url":"https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805","title":"Bremelanotide (subcutaneous route)","quote":"Stomach or bowel problem (eg, slow gastric emptying)—Use with caution. May make this condition worse and decrease the absorption of oral medicines.","summary":"Official caution on gastric effects.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:16:02.106Z","link_status":"http_403","quote_status":"unverified","prev":"41c499b11caea3327df1edf2d15459d533486ebe7e7a82d387322ca215cd8427","hash":"c613e26a32fd644a3cc2966e3fbe90fa778b6f26165d7906e7c44a73c63ca574"}]}